All In Biotech

Drug Trial Radar · NCT01790503

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Last checked: Nov 20, 2026Latest source record: Jun 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

65

Actual

Start

Jul 18, 2013

Primary completion

Nov 3, 2017

Study completion Mar 4, 2020

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Plexxikon
First posted
Feb 13, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).

Conditions

  • Patients With Newly Diagnosed Glioblastoma

Interventions

  • PLX3397Drug

  • Radiation TherapyRadiation

  • TemozolomideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summary of the Median Progression-free Survival (mPFS) in the Combined 800 mg, 5 Days/Week Dose GroupTime frame: Assessed from date of first dose administered to date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years 4 months.
  2. Summary of the Median Progression-free Survival (mPFS) in the Study Group Compared With Historical Control From Medical LiteratureTime frame: Assessed from date of first dose administered to date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years 4 months.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Columbia University Medical Center

    New York, New York

  • James Cancer Hospital/Ohio State University

    Columbia, Ohio

  • Huntsman Cancer Institute University of Utah

    Salt Lake City, Utah

  • Seattle Cancer Care Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.